IgA肾病治疗研究进展及展望

Research Progress and Prospects of IgA Nephropathy

IgA肾病是全球最常见的原发性肾小球疾病,其是一种缓慢进展的疾病,目前尚无特异性治疗方法,且糖皮质激素和免疫抑制剂的治疗作用一直存在争议。随着生物科学和医学技术进步,肠道黏膜免疫、补体系统、内皮素(ET)受体及B细胞活化因子(B cell activating factor,BAFF)/增殖诱导配体(a proliferation-inducing ligand,APRIL)系统等被证实在IgA肾病发生发展中发挥重要作用。这些新进展为推测发病机制提供了理论依据,也为研发新型药物提供了方向。本文主要对IgA肾病药物治疗现状及其存在的问题进行综述。

IgA nephropathy is the most common primary glomerular disease in the world.It is a slow-progressing disease with no specific treatment at present,and the therapeutic effects of glucocorticoid and immunosuppressant have always been controversial.As biological science and medical technology advance,intestinal mucosal immunity,complement system,endothelin(ET)receptors,and B cell activating factor(BAFF)/a proliferation-inducing ligand(APRIL)system etc has been confirmed to play an important role in the occurrence and development of IgA nephropathy.These new developments provide a theoretical basis for predicting the pathogenesis and a direction for developing new drugs.This article mainly reviews the treatment status and existing problems of IgA nephropathy drug treatment.